Key result
Concomitant use of calcium channel blockers and statins did not increase the risk of peripheral edema or myalgia compared to monotherapy.
Why the study?
CCBs and statins are frequently co-prescribed to prevent cardiovascular diseases, but their concomitant use may cause drug-drug interactions and increase adverse effects.
Does the concomitant use of calcium channel blockers and statins increase the risk of adverse effects compared to either treatment alone in adults?
Meta-Analysis (n=1,053,198)
Does the concomitant use of calcium channel blockers and statins increase the risk of adverse effects compared to either treatment alone in adults?
The concomitant use of statins and calcium channel blockers appears safe in the short term, with no significant increase in peripheral edema, myalgia, or treatment discontinuation compared to monotherapy.
Answers are grounded in this paper and cite their sources.
Supports safe CCB-statin co-prescription without added adverse risks; confirms short-term tolerability and extends meta-analytic evidence.
Calcium channel blockers (CCBs) and statins are commonly combined to prevent cardiovascular diseases (CVDs). However, their concomitant use may lead to drug-drug interactions (DDIs) and increased adverse effects (AEs). This systematic review and meta-analysis aimed to evaluate the evidence of adverse effects (AEs) associated with the calcium channel blockers (CCBs) and statins concomitant use. We searched MEDLINE, Embase, Web of Science, and CENTRAL from database inception to 4 April 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting AEs of CCB-statin combinations compared with CCB or statin treatment in adults. Outcomes assessed included CCBs- and statins-associated AEs, treatment discontinuation, hospitalization, and all-cause mortality. Meta-analyses of similar outcomes were performed to estimate pooled Odds Ratios (OR) with 95% confidence intervals (CI). Of 9,737 articles screened, 20 studies (n = 1,053,198) were included. Peripheral edema, myalgia, and discontinuation were most reported in 11, 7, and 9 studies, respectively. Meta-analyses demonstrated no significant differences in the risk of peripheral edema (OR 1.03, 95% CI 0.14–1.48), myalgia (OR 1.33, 95% CI 0.63–2.79), or discontinuation (OR 0.78, 95% CI 0.50–1.23 for CCB-statin vs. CCB; OR 0.97, 95% CI 0.68–1.38 for CCB-statin vs. statin). However, evidence of other AEs was inconsistent and limited. CCB-statin combination appears generally safe in a short-term use (3 to 6 months). Further research is warranted to clarify the long-term risk of AEs.
No takes yet. Share an insight, caveat, or question.
Zulfa et al. (2026) conducted a meta-analysis in Cardiovascular diseases (prevention) (n=1,053,198). Concomitant use of calcium channel blockers (CCBs) and statins vs. CCB or statin treatment alone was evaluated on Peripheral edema (OR 1.03, 95% CI 0.14-1.48). Concomitant use of calcium channel blockers and statins did not increase the risk of peripheral edema or myalgia compared to monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: